^
Association details:
| Biomarker: | FBXW7 mutation |
|---|---|
| Cancer: | Solid Tumor |
| Drug: | lunresertib (RP-6306) (PKMYT1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Title:
Repare Therapeutics to Highlight Program Progress for RP-6306 at Today’s Virtual Investor Day Event
Published date:
04/08/2021
Excerpt:
Repare Therapeutics Inc....will be reviewing the compelling pre-clinical anti-tumor activity of RP-6306, our first- in-class, selective, oral inhibitor of PKMYT1 to treat CCNE1-amplified, FBXW7-altered and other undisclosed PKMYT1 inhibitor-sensitive cancers. Our in vivo and other pre-clinical data indicate that RP-6306 can selectively inhibit tumors with these specific alterations when used as a monotherapy and in combination with other agents.
